Funding Opportunities In Us

The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.

This Funding Opportunity Announcement encourages applications using community-engaged research methods to investigate the potential health risks of environmental exposures of concern to the community and to implement an environmental public health action plan based on research findings. The overall goal is to inform and support efforts to prevent or reduce exposure to harmful environmental exposures and improve the health of a community.

The National Institutes of Health (NIH) hereby notify recipient organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of recipient organization status, often referred to in this announcement as Successor-In-Interest, may be submitted to this NOFO. Applications for change of recipient organization status are considered prior approval requests (as described in Section 8.1.2.8 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award.Although successor-in-interest requests may be submitted through this NOFO, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) [https://www.oar.nih.gov/hiv-policy-and-research/research-priorities] in the areas of hearing, balance, taste, smell, voice, speech, or language. For applications with a clinical trial, only low risk clinical trials will be supported.

To advance the field of patient-centered clinical decision support through research that tests tools and resources in real-world settings.

The NICHD Small Research Grant Program (Clinical Trial Required) supports clinical trials that fall within the NICHD mission. This funding opportunity announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required FOA.

This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.

The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

The National Institute of General Medical Sciences (NIGMS) invites applications for renewal of eligible Centers of Biomedical Research Excellence (COBRE) grants. The objective of the COBRE initiative is to strengthen an institution's biomedical research infrastructure through the establishment of a thematic, multi-disciplinary center and to enhance the ability of investigators to compete independently for NIH individual research grants or other external peer-reviewed support. COBRE awards are supported through the Institutional Development Award (IDeA) Program, which aims to foster health-related research by increasing the competitiveness of investigators at institutions located in states with historically low aggregate success rates for grant awards from the NIH. The goal of this FOA is to support existing COBRE Phase 1 Centers by further strengthening the research infrastructure and to continue the development and support of a critical mass of investigators with the expertise in the Center's scientific interest areas.

This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the ?participating NIH Institutes or Centers. This program is intended to support New Investigators and At-Risk Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences.Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIHs Interest in Diversity), are eligible to apply. Investigators from categories A and B are particularly encouraged to work with their institutions to apply

Reissue of PAR-21-325: The purpose of this Funding Opportunity Announcement (FOA) is to enhance the diversity of the mental health research workforce by providing dissertation awards in all research areas within the strategic priorities of the NIMH to individuals from backgrounds underrepresented in biomedical, behavioral, clinical and social sciences research. This award supports the completion of the doctoral research project.

The purpose of the NHLBI Career Pathway to Independence in Blood Science Award for Physician Scientists (R00) is to increase and maintain a strong cohort of new and talented, NHLBI supported, independent investigators in blood science. This program is designed to facilitate a timely transition of outstanding blood science researchers with a clinical doctorate degree from mentored research positions to independent, tenure-track or equivalent faculty positions. This NOFO offers the opportunity for current RFA-HL-20-001 or RFA-HL-20-002 K99 awardees to apply for the independent phase (R00) of the program. In the R00 phase, successful blood science physician scientist scholars will receive up to three years of funding to continue their research activity with support from this FOA, which will require updated research plans and a limited competition review.

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications from Small Business Concerns (SBCs) to pursue the development of improved clinical diagnostics or the development of alternative clinical diagnostics that address health disparities created by clinical laboratory assays and/or point-of-care devices that fail to incorporate diverse patient groups. Applicants will identify a potential issue within a clinical diagnostic or group of clinical diagnostics that perpetuates health inequity and disparities, clearly define the disparity issue, and develop a solution to address the concern.

The purpose of the NIH HEAL InitiativeSM Pathway to Independence Award (K99/R00) program is to enhance workforce diversity in the research workforce and maintain a strong cohort of new and talented independent investigators conducting Pain and/or SUD research, in order to increase the pool of diverse and independent investigator workforce in research areas supported by the NIH HEAL InitiativeSM. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL InitiativeSM. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, an ancillary clinical trial, or an independent Basic Experimental Studies with Humans (BESH). Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing an independent clinical trial, a clinical trial feasibility study, an ancillary clinical trial, or an independent BESH as lead investigator, should apply to the companion FOA (RFA-NS-22-024).

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

The ORWH and participating organizations and institutes seek applications for Specialized Centers of Research Excellence (SCORE) on Sex Differences. The Centers of Excellence will support interdisciplinary approaches to advance translational research on sex differences. Each SCORE institution should develop a research agenda bridging basic and clinical research underlying a health issue that is pertinent to improving the health of women.

NIMHD intends to support innovative multi-disciplinary (such as behavioral, biological, environmental, social, cultural) and multi-level (e.g., patient, clinician, interpersonal, community) research designed to understand and address how optimizing patient-clinician relationships/communication affects health care outcomes for patients from populations with health disparities.

The purpose of this Notice of Funding Opportunity (NOFO) is to invite Small Research Grant (R21) applications that propose to study the ethical, legal, and social implications (ELSI) of human genetics and genomics. Applications may propose studies using either single or mixed methods. Direct involvement of key stakeholders where appropriate is encouraged. These applications should be for small research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.

This Small Research Grant (R03) will support meritorious projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this NOFO will support projects covering a wide range of topics related to AD/ADRD. The overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise.

The purpose of this Notice of Funding Opportunity announcement (NOFO) issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is to announce the re-competition of the Womens Reproductive Health Research (WRHR) Career Development Program. This national group of mentored institutional career development programs trains junior faculty who have recently completed postgraduate clinical training in obstetrics and gynecology and are committed to an independent research career in women's reproductive health. The goal of this program is to continue to build the national capacity of outstanding junior clinician-investigators who will strengthen the field of obstetrics and gynecology and contribute to the improvement of womens health.

The goal of the Bridges to the Baccalaureate Research Training Program is to provide structured activities to prepare a diverse cohort of research-oriented students to transfer from associate degree-granting to baccalaureate degree-granting institutions and complete a baccalaureate degree in biomedical research fields. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements. This program requires strong partnerships between at least two post-secondary educational institutions offering science, technology, engineering, or mathematics (STEM) degrees. At least one partner must be an institution that offers the associate degree as the highest STEM degree and the other partner(s) must offer baccalaureate degrees in biomedically relevant STEM fields. Upon completion of the Bridges to the Baccalaureate Research Training program, trainees are expected to be well positioned to pursue a research-oriented biomedical higher degree program or enter careers in the biomedical research workforce.This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.

This announcement invites applications for basic research projects on chemical warfare agents, toxic industrial chemicals, and pesticides that have primary or secondary effects on the nervous system. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. Projects supported by this NOFO are expected to generate data that elucidate mechanisms of toxicity of these agents, possible new manifestations of toxic exposures, and potential new targets for therapeutic development.

This Notice of Funding Opportunity (NOFO) invites applications to usethe NIH INCLUDE Project (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) to access resources to generate a large volume of integrated genomic and multi-omics data to facilitate discovery of the molecular mechanisms of health conditions related to Down syndrome. These data, and associated clinical and phenotypic data, will become part of the INCLUDE Project data resource for sharing with the research community. No funding will be provided directly to applicants under this NOFO. Applicants are encouraged to propose omics essays of existing biospecimens collected from individuals with Down syndrome and controls. The program will accept applications that propose whole genome sequencing, including both short-read and long-read, exome, epigenome, and transcriptome sequencing, as well as proteomic, metabolomic, and single-cell RNA sequencing and ATAC sequencing, when justified. Applicants are encouraged to propose cohorts of underrepresented racial and ethnic groups or to increase racial and ethnic representation of existing collections. The omics data and related phenotypic data will be deposited in a public INCLUDE Project controlled-access database.

The goals of this initiative are to examine mechanisms of reciprocal interactions between HIV-associated neuroinflammation and CNS persistence in the setting of excellent virologic control using novel CNS cell systems, organoid models and single cell technologies

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Mental Health (NIMH) R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs and advance the priorities outlined in the Office of AIDS Research (OAR) Annual Strategic Plan and the research program priorities of the NIMH Division of AIDS Research (DAR). To accomplish the stated over-arching goal, this NOFO will support creative educational activities with a primary focus on Research Experiences and Mentoring Activities that either capitalize on existing networks of collaborating investigators or develop institute-based research education programs. Both research experiences and mentoring activities are required; research experiences are expected to be primary. Research Education Programs are expected to enhance the professional development of the participants and foster a career trajectory towards independent research in the mental health of HIV/AIDS.

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage institutions to propose creative and innovative institutional research career development programs which will prepare clinically trained vision scientists for independent research careers. This NOFO is intended to expand and strengthen the community of clinician investigators engaged in vision research. This Notice of Funding Opportunity (NOFO) allows the appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator as part of their research and career development program. For this career development program scholars are limited to clinical trials that are minimal risk. The existing clinical trial must be a NIH-defined clinical trial that fulfills the NIH requirement for minimal risk trial. A minimal risk trial is one in which the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. For the purposes of this announcement, institutions are highly encouraged to recruit prospective PIs/PDs, mentors, and scholars from underrepresented racial and ethnic groups as well as individuals with disabilities as described in the NOT-OD-22-019 in all of its programs.

This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see TEMP9971).Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.

NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing research and also to extend the focus of research to drug abuse and addiction. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are encouraged. An application should integrate and promote research in existing funded projects, to achieve new and creative directions. It is expected that individual core activities reflect a relationship to the integrating theme of the Center and the Center is expected to provide research opportunities and experiences to new investigators , and share findings, data and their resources, consistent with achieving the goals of the program.

The primary purpose of the AHRQ Patient-Centered Outcomes Research (PCOR) Mentored Clinical Investigator Career Development Award (K08) program is to provide support for qualified individuals for an intensive, mentored research career development experience in comparative effectiveness research (CER) methods as applied to patient-centered outcomes research (PCOR).

The objective of this Notice of Funding Opportunity (NOFO) is to solicit applications to conduct institutional climate assessments using validated survey instruments and to develop action plans for positive change in the recruitment, hiring, retention, and advancement of faculty, including those from groups underrepresented in biomedical and behavioral research (see NIH Interest in Diversity). The plans for self-studies should lead to institutional culture change by identifying perceptions, attitudes, and concerns, about, for example, inequities, micro-aggressions, institutional racism, and bias. The self-studies should provide a foundation for the development of an action plan to enhance diversity, equity, inclusion, and accessibility (DEIA) outcomes in the recruitment, hiring, retention, and advancement of faculty.

Reissue of RFA-NS-18-019: Understanding the dynamic activity of neural circuits is central to the NIH BRAIN Initiative. The invention, proof-of-concept investigation, and optimization of new technologies through iterative feedback from end users are key components of the BRAIN Initiative. This FOA seeks applications to optimize existing or emerging technologies through iterative testing with end users. The technologies and approaches should have potential to address major challenges associated with recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in the central nervous system (CNS). These technologies and approaches should have previously demonstrated their transformative potential through initial proof-of-concept testing and are now ready for accelerated refinement. In conjunction, the manufacturing techniques should be scalable towards sustainable, broad dissemination and user-friendly incorporation into regular neuroscience research.Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as optical, electrical, magnetic, acoustic or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis.

This Notice of Funding Opportunity (NOFO) invites applications to develop and implement multi-site Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.

NIMH seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions. This FOA is intended to support the development of digital health test beds that leverage well-established digital mental health platforms,to rapidly refine and optimize existing evidence-based digital health interventions and conduct clinical trials testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness.

Reissue of the PA-18-401. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD).

The goal of this FOA is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with NIDA funding priorities detailed here (https://www.drugabuse.gov/funding/funding-priorities) or within the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from those who can contribute to diversifying the research workforce as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031).

This R21 funding opportunity encourages projects that test, in animals and/or humans, whether modifying electrophysiological patterns can improve cognitive, affective, or social processing. This R21 has a companion R01 (TEMP-10327). The proximal goal of this FOA (and its companion R01) is to encourage investigators to test whether modifying specific patterns of coordinated neural activity in vivo can improve cognitive, social, or affective processes. These studies should be based on a rational understanding of the role of specific neural activity rhythms in, for example, the routing of information among brain regions or in improving the ability of afferent information to affect local processing via coherence of underlying oscillatory activity.

This Funding Opportunity Announcement (FOA) solicits innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Divisions research priorities.

The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences.

he NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well designed and well executed clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm.

The goal of the NIGMS Predoctoral Basic Biomedical Sciences Research Training Program is to develop a diverse pool of well-trained scientists available to address the Nations biomedical research agenda. Specifically, this funding opportunity announcement provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation.

The purpose of this Notice of Funding Opportunity (NOFO) is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. NLM seeks applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. Applications seeking to advance the understanding of how informatics tools, systems, and platforms can best present the results, interpretation, and limitations of personalized assessments for the benefit of individuals are encouraged. Applications should include end user engaged approaches and real-world evaluation to inform the design of generalizable, reusable, and scalable personal health informatics tools, systems, and platforms for the benefit of individuals in understanding and improving their health.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this NOFO, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally

This RFA will act as a parent RFA for the HEAL initiative Translation to Practice Team, specifically encouraging translational dissemination and implementation research focused on addressing overdose deaths and the intersection of pain and OUD. This RFA will function in tandem with targeted NOSIs that announce more specific areas of focus. For FY23, this currently includes the Workforce NOSI (formerly an RFA) and the Violence and Trauma NOSI (also formerly an RFA). It has a companion R33 RFA and is expected to run for 2 years (FY23 and FY24).

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

NIOSH supports exploratory and developmental research projects (R21) that address issues related to diagnostic or treatment uncertainty with respect to individuals receiving monitoring and/or treatment under subtitle B of the James Zadroga 9/11 Health and Compensation Act of 2010 (Public Law 111–347, as amended by Public Laws 114–113, 116–59 and 117-328). World Trade Center (WTC) responders, screening-eligible WTC survivors, and certified-eligible WTC survivors comprise the population targeted for the research project.Lifestyle medicine is a highly valuable, evidence-informed clinical approach focused on preventing, managing, and reversing many types of chronic diseases certified as WTC-related health conditions by the WTC Health Program. By focusing on sustainable health behaviors and lifestyle factors (including these 6 pillars: nutrition and diet, sleep hygiene, stress management and positive psychology, physical activity, social connectedness, and avoidance of harmful substance use), lifestyle medicine has the potential to: limit current disease progression, prevent development of additional chronic diseases, and improve health outcomes, overall member well-being, quality of life, and member satisfaction with the Program.To help maximize the impact of the WTC Health Program FY2024 lifestyle medicine research, NIOSH seeks to achieve a suitable mix of projects and interventions focusing on sustainable health behaviors and the lifestyle factors described previously. All these sustainable health behaviors and lifestyle factors influence disease progression and recurrence, survival, quality of life, and other health-related outcomes among the 9/11-exposed population. Research funded by the WTC Health Program is primarily intended for the benefit of the 9/11-exposed population. It is not required that project findings be generalizable to other populations.The NIOSH/WTC Health Program R21 grant is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development which assess the feasibility of new areas of investigation with the potential to enhance treatment effectiveness and diagnostic practices. These studies may lead to breakthroughs in a particular area, or to the development of new techniques, agents, methodologies, models, or approaches with major clinical impacts. These studies are expected to break new ground or extend prior discoveries toward new directions or uses. Applicants are expected to propose research approaches for which there is likely to be minimal or no preliminary data.The WTC Health Program Research webpage provides comprehensive information and tools for researchers. The research agenda, publication library, and other resources, including the Funding Dashboard, can also be found there (e.g., awarded project details such as publications, topics, populations, funding awarded, and the principal investigators and their institutions).

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientist.

Through this Notice of Funding Opportunity (NOFO) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this NOFO is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" r "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this NOFO encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

This notice of funding opportunity (NOFO) will support junior faculty investigators involved in aging and Alzheimer's Disease (AD) and AD-related dementia (ADRD) research from low- and middle-income countries (LMICs), as defined by the World Bank. This NOFO will support proposals submitted from LMIC institutions. and through this NOFO, NIA will: (1) Support junior investigators from LMICs to conduct aging, AD and/or ADRD research in their respective LMICs; and (2) Support the career development of junior faculty investigators as future leaders in aging, AD and/or ADRD research from LMICs. In support of the program's goal, this NOFO invites applications that will yield pilot data, resources and experience for subsequent aging, AD and/or ADRD research projects. In addition, candidates are encouraged to seek out a supportive research environment that will achieve the goal of fostering the career development of junior investigators.

The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PA-18-NNN ).

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs.

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this NOFO are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this NOFO aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

This Notice of Funding Opportunity (NOFO) invites eligible academic or research institutions to apply for funding support to purchase latest scientific equipment that will enhance and modernize research-supporting operations of existing shared biomedical research facilities. Targeted are laboratory research core facilities, animal research facilities, and other similar shared-use research spaces. The goal of this NOFO is to strengthen research-auxiliary activities of biomedical research facilities and to enhance the efficiency of their operations. The NOFO does not support the purchase of scientific research instruments or their components, nor components of building-level infrastructure equipment that indirectly support research activities.

The purpose of this notice of funding opportunity (NOFO) is to support research towards identifying and characterizing neuroimmune networks, communication pathways, and targets that reside within neuroimmune axes, in the context of HIV and substance use. This NOFO will also support research on the discovery of novel modulatory probes/tools that can advance our understanding of the regulatory mechanisms by which neuroimmune interactions contribute to HIV and substance use disorder comorbidity.

The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. This research activity includes the development and testing of new interventions and expansion of existing effective interventions as well as the implementation of these integrative preventive activities in diverse settings and populations. Six areas of research are of primary interest related to alcohol use and related mental health and substance use comorbidities. These include but are not limited to 1) PrEP Utilization, 2) Treatment as Prevention (TasP), 3) Integration of Preventive Intervention Strategies, 4) Prevention-related Cross-cutting Research, 5) Syndemic Approaches and, 6) Implementation and Operations Research.

The National Institutes of Health (NIH) hereby notifies NIH award recipients that funds may be available for revision applications to support the expansion of existing projects and/or programs within the awarding IC identified in the competitive revision Notice of Special Interest (NOSI). Applications for Revisions will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), in accordance with NIH peer review policy and procedures, using the stated review criteria. Only applications submitted in response to a NOSI published by an NIH Institute or Center will be allowed to apply to this NOFO.

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage clinical research that will identify and validate novel targets for non-invasive brain stimulation (NIBS) and SUD-relevant neurobiological, cognitive, and behavioral responses to NIBS that precede clinical outcomes like reduced craving or drug use. Applications are expected to be exploratory and developmental in nature. As such, these studies may involve considerable risk of failure but may lead to a breakthrough in a particular area that could have a major impact on SUD research involving NIBS. This NOFO uses a R61/R33 Phased Innovation award activity code to support applications that propose mechanistic studies designed to understand a behavior or biological process, the pathophysiology of a disease, or the mechanism of action of an intervention. In addition, applications must meet the NIH definition of a clinical trial. NIH defines a clinical trial as A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. (NOT-OD-15-015)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NHGRI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development. Proposed short courses are expected to facilitate the development of a cadre of investigators with the requisite research skills to advance the mission of NHGRI. Applications are encouraged that propose innovative, advanced-level courses that are intended to disseminate new knowledge, analyses, methods and techniques related to the scientific, medical, ethial, social and/or legal areas of genomics research.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Courses for Skills Development Research Experiences Mentoring Activities

This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

This Funding Opportunity Announcement (FOA) invites applications to the National Institute on Aging's (NIA) Small Business Innovation Research (SBIR) program. The aim of this FOA is to support research that may lead to the development of innovative products and/or services that have the potential to advance progress in preventing and treating Alzheimer's disease (AD) and AD-related dementias (ADRD) and/or caring for and treating patients living with AD/ADRD.

| The purpose of the NIOSH Support for Conferences and Scientific Meetings (R13) is to support high quality scientific meetings, conferences, and workshops that are relevant to NIOSH’s scientific mission and that promote occupational safety and health, NIOSH program priorities, and public health. The conference program is integral to the overall mission of NIOSH. An application should address and advance important areas of research in the field of occupational safety and health of particular interest to NIOSH programs and the National Occupational Research Agenda. A conference or scientific meeting is defined as a gathering, symposium, seminar, workshop or any other organized and formal meeting where persons assemble in person or meet virtually to coordinate, exchange, and disseminate information or to explore or clarify a defined subject, problem, or area of knowledge. Applications for training-only events will not be considered under this announcement. |

Through this Notice of Funding Opportunity (NOFO), the National Institutes of Health (NIH) aims to facilitate the career development and transition of investigators new to entrepreneurship with an interest in small business by simultaneously supporting their entrepreneurial development and the conduct of research and development under their direction. This NOFO supports small business concerns (SBCs) in employing and developing researchers as entrepreneurial Program Directors/Principal Investigators (PDs/PIs). In addition to augmenting scientific research staff and supporting research and development efforts at SBCs, a major component of this NOFO is entrepreneurial training, mentoring, and career development of the PD/PI. Optimal PDs/PIs for this award are scientists and professionals with strong research, technology development, and/or healthcare delivery skills and experience, but limited entrepreneurial and independent research project leadership experience. PDs/PIs are expected to grow their entrepreneurial skillset while working in a small business to develop promising technologies and products that align with NIH's mission to improve health and save lives.

This Notice of Funding Opportunity (NOFO) encourages pilot effectiveness, implementation, data science, and services research studies that will advance data-driven learning health care in behavioral health treatment settings, leading to better knowledge and tools for implementing, sustaining, and optimizing evidence-based, high quality, and equitable mental health services in community settings. Pilot studies could examine the adoption and sustainability of evidence-based practices in community-based settings that deliver care to people with mental illness including, but not limited to, Certified Community Behavioral Health Clinics.

Awarded activities will facilitate the translation of novel recording and modulation technologies that can be used to treat and/or diagnose central nervous system (CNS) diseases and disorders and to better understand the human CNS, from proof of concept up to the stage of readiness for first in human (FIH) studies. Technologies may incorporate any signal modality (e.g., electrical, optical, magnetic, acoustic) or a combination thereof. Diverse team-based applications that integrate appropriate domains of expertise are encouraged.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. The R21 FOA is intended to encourage exploratory projects that are at an early conceptual stage feasibility study (inception through preliminary development) to demonstrate the core functional capabilities of the proposed approach. The proposed projects may involve considerable risk and should be aimed at producing breakthroughs in microbial-based cancer therapy, imaging, or diagnosis. This funding opportunity is part of broader NCI-sponsored research on microbial-based cancer therapy.

The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.

The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

The purpose of this NIH HEAL Initiative PAINCare Clinician Training Program(PCTP): Mentored Clinical Scientist Development Awards (K08) (BESH)is to support a cohort of new and well-trained, independent investigators. The program will provide independent NIH research support during the early-career phase to help awardeesestablish independent research programs in areas support by the NIH HEAL InitiativesClinicalResearch in Pain Management program.

This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Insitute of Neurological Disorders and Stroke R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs.To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on research experiences, designed to foster the development of physicians as research scientists in areas relevant to the NINDS mission. The research experiences will prepare clinicians to successfully compete for individual NIH mentored career development awards, or where appropriate, independent research awards. This FOA will also support educational activities such that participants of the R25 are expected to attend and participate in an annual workshop specific to this FOA to present their work, discuss progress and plans towards transitioning to the next career stage and to network with other researchers and leaders in their fields. Such success will facilitate their transition from resident/fellow to physician-scientist, and will thus foster retention of a cadre of physician-scientists who will conduct research into the mechanisms of, etiology, and treatment of neurological diseases.

The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of childrens language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable toolsto further our understanding of childrens language development and/or impairment, and predictors thereof.

This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity of thought in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA.

Reissue of RFA-MH-20-525. The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic, or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the NIMH Strategic Plan.

This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support two types of cancer centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas. The purpose of both types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious programs in laboratory, clinical, and population research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of shared resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences.

This NOFO provides support using the SBIR cooperative agreement mechanisms for the development of MATChS. Applications considered responsive to this would include those proposing research and development of tools and turnkey technologies for higher throughput automated measures with on-line sensing, rapid acquisition and analysis of data to reduce manual handling. Funded projects will result in an increased availability of miniaturized automated tissue chip platforms for use in drug development and across multiple applications as a major research tool in biomedical research laboratories. As a cooperative agreement, small business concerns (SBCs) will be expected to develop milestones and benchmarks, and work with NIH staff towards progress in the aims of the project to develop an automated system and demonstrable pathways to commercialization.

Individuals in the US justice system are disproportionately likely to have SUD/OUD, are at high risk for opioid withdrawal upon incarceration, and are at elevated risk for overdose post-release if they have not received MOUD while detained. Most US jails do not offer MOUD to everyone who could benefit from them. JCOIN focuses on the translation of research-to-practice to address the overdose crisis in the context of the criminal justice system specifically, increasing delivery of and access to MOUD. A portfolio of research projects conducts hybrid effectiveness-implementation trials to address key barriers to delivery of evidence-based OUD treatments to justice-involved populations. This is the only HEAL initiative with a primary focus on justice-involved populations and criminal-legal systems.

The National Institute of General Medical Sciences (NIGMS) invites applications for Institutional Development Award (IDeA) Networks of Biomedical Research Excellence (INBRE) awards from investigators at biomedical research institutions that award doctoral degrees in the health sciences or sciences related to health or at independent biomedical research institutes with ongoing biomedical research programs funded by the NIH or other Federal agencies within the IDeA- eligible states. The purpose of the INBRE program is to augment and strengthen the biomedical research capacity of IDeA-eligible states. The INBRE program represents a collaborative effort to sponsor research between research intensive institutions and primarily undergraduate institutions, community colleges, and Tribally Controlled Colleges and Universities (TCCUs), as appropriate.

The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI. Only applications submitted in response to an Emergency NOSI published by an IC will be allowed to apply to this NOFO.

This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.

Through this notice of funding opportunity (NOFO) as a request for applications (RFA), the National Cancer Institute (NCI) intends to support pilot/exploratory research that expands the current understanding of the confluence of cancer stigma and HIV stigma among people with HIV (PWH) diagnosed with cancer; assesses the impact of these two converging stigmas on cancer outcomes among PWH with cancer; leverages stigma reduction interventions at multiple levels to intervene on modifiable mechanisms of stigma that contribute to negative cancer outcomes among PWH with cancer; and promotes research in domestic and international contexts, focusing on regions in which the HIV-cancer burden is elevated.

The Agency for Healthcare Research and Quality (AHRQ) announces its interest in supporting conferences through the AHRQ Single-Year and Multiple-Year Conference grant programs (R13). AHRQ seeks to support conferences that help further its mission to produce evidence to make health care safer, higher quality, more accessible, equitable and affordable, and to work with HHS and other partners to make sure the evidence is understood and used (http://www.ahrq.gov/funding/policies/foaguidance/index.html).

The Maximizing Investigators' Research Award (MIRA) provides support for the program of research in an investigator's laboratory that is within the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this program will: Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively; Increase flexibility for investigators to follow important new research directions within the NIGMS mission as opportunities arise, rather than being bound to specific aims proposed in advance of the studies; More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs; Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research; Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment. This FOA allows applications from eligible NIGMS-funded investigators and from New Investigators proposing research within the scientific mission of NIGMS. The FOA also allows renewal applications from all current MIRA grantees (established investigators and those previously funded as early-stage investigators). PD/PIs who are currently Early Stage Investigators (ESIs) should apply through the ESI MIRA FOA and should not apply through this FOA.

This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.

The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (FOA #).

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). As part of the INCLUDE Project, NIH is interested in expanding and diversifying the skilled DS clinical research workforce. The intent of this Funding Opportunity Announcement (FOA) is to encourage applications that develop creative and innovative short courses to train the next generation of DS researchers in state-of-the-art clinical research skills that will improve the understanding of the co-occurring clinical features in DS and support development of new treatments for health conditions experienced by those with DS.

The purpose of this funding opportunity is to reduce health disparities through the development and translation of appropriate medical technologies. The NIH defines health disparities as differences in the incidence, prevalence, morbidity, mortality, and burden of diseases and other adverse health outcomes that exist among specific population groups. These population groups include racial and ethnic minorities (African Americans, American Indians, Alaska Natives, Asian Americans, Hispanic Americans, Native Hawaiians, and other U.S. Pacific Islanders, as well as subpopulations of all of these racial/ethnic groups), socioeconomically disadvantaged individuals, sexual and gender minorities, and medically underserved populations including individuals residing in rural and urban areas (see https://www.nimhd/nih.gov/about/overview/). This program seeks advances in medical technologies to reduce health disparities associated with diseases, illnesses, and conditions of public health importance. This announcement encourages applications to develop medical devices, imaging systems, robotic systems, biomaterial interfaces, synthetic biological systems, mathematical and modeling solutions, and other technologies to address the healthcare needs of populations that experience health disparities. Proposed medical technologies must have the following basic characteristics: effective, affordable, culturally acceptable, and easily accessible to those who need them. Responsive grant applications will involve a formal collaboration with a healthcare organization or public health agency serving one or more populations that experience health disparities.

The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.

The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

The NIH Office of Research on Women's Health (ORWH) and participating NIH Institutes and Centers invite institutional career development award applications for Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Career Development Programs, hereafter termed "Programs". Programs will support mentored research career development of junior faculty members, known as BIRCWH Scholars, who have recently completed clinical training or postdoctoral fellowships, and who will be engaged in interdisciplinary basic, translational, behavioral, clinical, and/or health services research relevant to the health of women and, where appropriate, the use of both sexes to better understand the influence of sex as a biological variable on health and disease. This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

The purpose of this Notice of Funding Opportunity (NOFO) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase will support research that is in the final states of preclinical development with potential for near-term clinical development. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion R33, PAR-23-205.

Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)

The objective of this NOFO is to notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for competitive revisions to enhance the diversity of the research workforce by recruiting and supporting students, post doctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health services research. This opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project

This Funding Opportunity Announcement (FOA) will accept applications for competing renewal or competitive revisions of ongoing clinical trials supported by the National Institute of Dental and Craniofacial Research (NIDCR). Extension of an ongoing clinical trial through a competing renewal application will be supported when there is need for additional time to complete the trial or when an extended period of follow-up is well justified to assess longer term outcomes. Competitive revisions will be supported when there is compelling justification for modifying the scope of the ongoing clinical trial. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the ongoing clinical trial for which they are planning a competing renewal or competitive revision prior to submitting an application to this FOA.

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and participating Institutes and Centers. New investigators at the time of award under this FOA will have/have had less than $125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

The purpose of this Notice of Funding Opportunity (NOFO) is to support multidisciplinary and innovative intervention research to understand and address maternal morbidity and mortality in the United States, particularly but not exclusively among racial and ethnic minority, socioeconomically disadvantaged, and underserved rural populations, with a focus on understudied healthcare factors. This is a new funding opportunity to advance the goals of the NIH Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE) Initiative. IMPROVE aims to understand the biological, behavioral, environmental, sociocultural, clinical, and structural factors that affect pregnancy-related and pregnancy-associated severe morbidity and mortality and build an evidence base for improved care and outcomes. The IMPROVE initiative supports research to reduce preventable causes of maternal deaths and improve health for women before, during, and after delivery. It includes a special emphasis on health disparities and populations that are disproportionately affected, such as racial and ethnic minority persons, very young women and women of advanced maternal age, and people with disabilities.

The purpose of this NOFO is to build upon the NIMH supported APN and further expand it into APN2 to include larger, more comprehensive studies that address current gaps in the field. The CC created under this initiative will further facilitate network-wide collaborative activities which will enhance the value of the unique data resource to be created by the network projects, develop much needed guidance to the scientific community and promote career development and research capacity building for investigators from low resource settings around the globe.

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).